Compare AstraZeneca plc (AZN) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs VanEck Junior Gold Miners — how do they compare? AstraZeneca plc trades at $166.9 (market cap $253.13B), while VanEck Junior Gold Miners trades at $98.56. The key difference: AstraZeneca plc pays a 1.92% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals.
| AZN | GDXJ | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $209.48 | $156.19 |
52-Week Low | $137.44 | $64.22 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
GDXJ (VanEck Junior Gold Miners ETF) trades at $95.40, down 3.55% with a bearish technical signal from moving averages. The fund has underperformed peers in 2026 with double-digit declines while other mining ETFs gained. Technical indicators show neutral oscillators but bearish momentum with key support at $92 and resistance at $97. Recent news highlights concerns about the fund's small-cap exposure and portfolio overlap issues.
The outlook remains challenging given GDXJ's 2026 underperformance and technical bearishness. Investment opportunity exists for contrarian bets on gold miner recovery, but risks include Federal Reserve policy uncertainty, weak small-cap gold miner fundamentals, and continued underperformance versus senior mining peers. The fund's high overlap with larger miners reduces diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
